Corcept Therapeutics Inc (CORT)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $11.92B
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Latest financial period: June 30, 2026
Filed with the SEC: July 29, 2026
Estimated earnings date: November 3, 2026
Profit #527 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 65.0% | 64.3% | 78.0% | 81.3% |
Growth #835 of 1484 companies
Payout #304 of 1484 companies
Safety #346 of 1484 companies
Price #1281 of 1484 companies
